Revance Therapeutics (RVNC) Insider Trading & Ownership

$5.26

+0.04 (+0.77%)

(As of 10:54 AM ET)

Current Insider Ownership Percentage: 5.10%
Number Of Insiders Buying (Last 12 Months): 0
Number Of Insiders Selling (Last 12 Months): 4
Amount Of Insider Selling (Last 12 Months): $143,642.48

Get RVNC Insider Trade Alerts

Want to know when executives and insiders are buying or selling Revance Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.

RVNC Insider Buying and Selling by Quarter

Ad Stansberry Research

$2 Trillion Disappears Because of Fed's Secretive New Move

$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being carried out by the Fed that has nothing to do with lowering or raising interest rates... but could soon have an enormous impact on your wealth.

Click here to see his new research now.

Revance Therapeutics Insider and Congressional Trades History

Transaction Type

Time Frame

Start Date

End Date

Export to Excel

Transaction Date	Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
4/16/2024	Erica Jordan	Insider	Sell	2,392	$3.80	$9,089.60
3/18/2024	Dustin S Sjuts	President	Sell	9,211	$5.04	$46,423.44
3/18/2024	Dwight Moxie	Insider	Sell	8,125	$5.04	$40,950.00
3/18/2024	Tobin Schilke	CFO	Sell	9,361	$5.04	$47,179.44

(Data available from 1/1/2013 forward)

RVNC Insider Trading Activity - Frequently Asked Questions

: The list of insiders at Revance Therapeutics includes Angus C Russell, Aubrey Rankin, Carey Oconnor Kolaja, Dustin S Sjuts, Dwight Moxie, Erica Jordan, Mark J Foley, and Tobin Schilke. Learn more on insiders at RVNC.
: 5.10% of Revance Therapeutics stock is owned by insiders. Learn more on RVNC's insider holdings.
: The following insiders have sold RVNC shares in the last 24 months: Carey Oconnor Kolaja ($70,600.00), Dustin S Sjuts ($1,606,029.41), Dwight Moxie ($1,789,465.12), Erica Jordan ($9,089.60), Mark J Foley ($6,866,970.12), and Tobin Schilke ($1,311,185.19).
: Insiders have sold a total of 407,960 Revance Therapeutics shares in the last 24 months for a total of $11,653,339.44 sold.

Revance Therapeutics Key Executives

Mr. Mark J. Foley (Age 59)
CEO & Director
Compensation: $1.26M
Mr. Tobin C. Schilke (Age 49)
CFO & Principal Accounting Officer
Compensation: $731.58k
Mr. Dwight O. Moxie (Age 48)
Chief Legal Officer & General Counsel
Compensation: $713.82k
Jessica Serra
Head of Investor Relations & ESG
Ms. Jeanie D. Herbert
Senior Director of Investor Relations & Corporate Communications
Ms. Taryn Conway
Vice President of Marketing
Ms. Amie Krause
Chief People Officer
Dr. Conor Gallagher
Head of Medical Affairs & Aesthetics
Dr. David A. Hollander M.B.A. (Age 49)
M.D., Chief Medical Officer of Global Therapeutics Franchise Lead
Ms. Erica Jordan (Age 47)
Chief Commercial Officer
1 recent trades